Clinical Trial · NCT04939610

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)

Overview

Brief Summary: Phase 1 of this study will evaluate the safety and tolerability of 177Lu-FAP-2286 and determine the recommended Phase 2 dose (RP2D) in patients with advanced solid tumors. Phase 2 of this study is designed to evaluate objective response rate (ORR) in patients with specific solid tumors.

Sponsor

Clovis Oncology

Phase

Phase 1/2

ClinicalTrials.gov

NCT04939610